NCT04509622 2022-05-05
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
AbbVie
Phase 3 Completed
AbbVie
Sunesis Pharmaceuticals
University of Arkansas